A recent study describes a new candidate anti-cancer drug, HB-19. In contrast to conventional anti-cancer drugs, HB-19 has a dual mechanism of action by independently targeting tumor cell growth and tumor. The molecular target of HB-19 is nucleolin expressed on the surface of all activated cells, in particular rapidly growing tumor cells and endothelial cells that play a key role in angiogenesis.
- Experimental anti-cancer synthetic molecule targets tumor cell growth and angiogenesisWed, 18 Jun 2008, 8:07:38 EDT
- Researchers gain new insights into how tumor cells are fedMon, 8 Aug 2011, 14:34:02 EDT
- Preventing tumor cells from refueling: A new anti-cancer approach?Thu, 20 Nov 2008, 17:57:20 EST
- New strategy to attack tumor-feeding blood vesselsMon, 6 Jun 2011, 10:05:48 EDT
- Wistar researchers show targeting 'normal' cells in tumors slows growthMon, 16 Nov 2009, 20:21:54 EST